Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Comron Hassanzadeh Image

      Comron Hassanzadeh, MD, MPH

      Department of GU Radiation Oncology, Division of Radiation Oncology

      About Dr. Comron Hassanzadeh

      Comron Hassanzadeh, MD, MPH, is an Assistant Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center. Dr. Hassanzadeh is the Associate Medical Director of The Proton Therapy Center and Co-Director of The Bone Metastasis Clinic. Dr. Hassanzadeh specializes in the management of patients with prostate, bladder, kidney, urethral, testicular cancers and patients with bone metastases. Prior to his appointment, he earned his medical degree from the University of Missouri Kansas City. He then completed a residency in Radiation Oncology at Washington University School of Medicine. During residency, he completed a Master of Public Health at the University of Missouri.

      Dr. Hassanzadeh has clinical expertise in a variety of radiation modalities including intensity modulated radiation (IMRT), proton therapy, stereotactic body radiation therapy (SBRT), brachytherapy, magnetic resonance guided radiation, and online adaptive radiation. He serves as the Principal Investigator on both prostate and bladder cancer trials aiming to define clinical practice. He has received extramural research support and his research has been presented at national/international conferences and published in high-impact, peer-reviewed journals. In addition, he has authored national guidelines for the management of prostate and bladder cancer through committee service in the American Radium Society, American Society for Therapeutic Radiation Oncology, and International Bladder Cancer Group.

      He currently serves in various leadership roles within organizations including NRG Oncology, American College of Radiation Oncology, American Society for Therapeutic Radiation Oncology, ECOG-ACRIN, International Bladder Cancer Group, Bladder Cancer Advocacy Network, Radiological Society of North America, American Radium Society, and American College of Radiology.

      Read More

      Present Title & Affiliation

      Primary Appointment

      Associate Medical Director, Proton Therapy Center, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Residency Associate Program Director, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Co-Director, Bone Metastasis Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Assistant Professor, Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Assistant Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Education & Training

      Degree-Granting Education

      2019University of Missouri Columbia, Columbia, Missouri, US, Master of Public Health (MPH)
      2017University of Missouri Kansas City, Kansas City, Missouri, US, MD
      2013Saint Louis University, St. Louis, Missouri, US, Medical Science, BS

      Postgraduate Training

      2018-2022Clinical Residency, Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri
      2017-2018Clinical Residency, Transitional Medicine, Mercy Hospital St. Louis, St. Louis, Missouri

      Licenses & Certifications

      2025Basic Life Support (BLS)
      2025Acute Cardiovascular Life Support (ACLS)
      2025Pediatric Advanced Life Support (PALS)
      2023American Board of Radiology (ABR), Radiation Oncology
      2022American Board of Radiology, Clinical Qualifying Exam
      2022Texas Medical Board
      2021American Board of Radiology, Physics Qualifying Exam
      2021American Board of Radiology, Biology Qualifying Exam
      2018United States Medical Licensing Exam (USMLE) Step 2 CS
      2017United States Medical Licensing Exam (USMLE) Step 2 CK
      2016United States Medical Licensing Exam (USMLE) Step 1

      Experience & Service

      Faculty Academic Appointments

      Chief Resident, Radiation Oncology, Washington University in St. Louis, St. Louis, MO, 2021 - 2022

      Assistant Chief Resident, Radiation Oncology, Washington University in St. Louis, St. Louis, MO, 2020 - 2021

      Administrative Appointments/Responsibilities

      Associate Medical Director, Proton Therapy Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present

      Bone Metastasis Clinic Director, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present

      Residency Program Associate Director, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present

      Genitourinary Medical Student Site Director, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present

      Bone Metastasis Clinic Genitourinary Chair, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present

      Bladder Working Group, Radiation Oncology Chair, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present

      Genitourinary Residency Education Site Director, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present

      Other Professional Positions

      Radiopharmaceutical Subcommittee Member, ACRO, 2026 - Present

      Texas Radiological Society, Alternate Councilor, Texas Radiological Society (TRS), 2026 - Present

      Genitourinary Cancer Core Committee Member, NRG Oncology, 2026 - Present

      Scientific Program Committee- GU Lead, ACRO, 2026 - Present

      Genitourinary Abstract Review Committee, American Society of Therapeutic Radiation Oncology (ASTRO), 2025 - Present

      New Practitioner Committee Chair, American College of Radiation Oncology, 2025 - Present

      Radiopharmaceutical Clinical Trials Collaborative, Radiation Oncology Lead, American Society of Therapeutic Radiation Oncology (ASTRO), 2025 - Present

      Education Committee: Palliative Track, American Society of Therapeutic Radiation Oncology (ASTRO), 2024 - Present

      Member at Large, Texas Radiological Society, Texas, 2024 - Present

      New Practitioner Committee, Vice Chair, American College of Radiation Oncology, 2024 - Present

      Theranostics Subcommittee, NRG Oncology, 2024 - Present

      Patient Centered Outcomes Research Committee, NRG Oncology, Houston, TX, 2023 - Present

      Core Committee Member, International Bladder Cancer Group (IBCG), Houston, TX, 2023 - Present

      Abstract Review Committee, American College of Radiation Oncology, 2023 - Present

      Developmental Therapeutics RT Subcommittee Member, NRG Oncology, Houston, TX, 2022 - Present

      Finance & Development Committee Member, American College of Radiation Oncology (ACRO), Houston, TX, 2022 - Present

      Genitourinary Cancer Committee Member, NRG Oncology, Houston, TX, 2022 - Present

      Genitourinary Cancer Committee, Bladder Working Group Member, NRG Oncology, Houston, TX, 2022 - Present

      Abstract Review Committee Member, American College of Radiation Oncology (ACRO), Houston, TX, 2021 - Present

      Radiology Leadership Institute Member, American Board of Radiology, St. Louis, MO, 2021 - Present

      New Investigators Committee Member, NRG Oncology, Houston, TX, 2021 - Present

      Membership Committee Member, American College of Radiation Oncology (ACRO), Houston, TX, 2021 - Present

      Treasurer and Radiation Oncology Representative, Missouri Radiological Society, St. Louis, MO, 2021 - 2022

      Medical School Tutor, MedSchoolCoach, National, 2020 - 2022

      Fellow, PrecisCa Consulting, Boca Raton, FL, 2020 - 2022

      Scientific Program Committee, Resident Chair, American College of Radiation Oncology (ACRO), N/A, 2020 - 2021

      Resident Committee Chair, American College of Radiation Oncology (ACRO), St. Louis, MO, 2020 - 2021

      Resident Scholarship Chair, American College of Radiation Oncology (ACRO), St. Louis, MO, 2019 - 2020

      Main Operations Manager, University of Missouri, Sojourner Free Health Clinic, Kansas City, MO, 2016 - 2017

      AOA Chapter President, University of Missouri Kansas City, Kansas City, MO, 2016 - 2017

      Council on Curriculum Student Chair, University of Missouri Kansas City, Kansas City, MO, 2014 - 2015

      Extramural Institutional Committee Activities

      GU Section Representative, NTS Benchmarking Committee, The University of Texas MD Anderson Cancer Center, 2026 - Present

      Lead- Documentation, Coding, Billing Workstream, Ethos Adaptive Working Group, The University of Texas MD Anderson Cancer Center, 2026 - Present

      Proton Therapy Center Lead, Technology Assessment Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

      Team Lead, Adaptive Billing Working Group, The University of Texas MD Anderson Cancer Center, 2025 - Present

      Member, Radiation Oncology Patient Experience Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

      Bone Metastasis Lead, Theranostics Working Group, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Panel Member, Radiation Oncology Fellowship Interview Panel Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Lead, Radiation Oncology Residency Program - Theranostics Pathway Lead, The University of Texas MD Anderson Cancer Center, 2024 - Present

      GU Representative, Radiation Oncology Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Associate Program Director, Radiation Oncology Residency Interview Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Radiation Oncology Lead, Bladder Cancer Algorithm Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Member, Genitourinary Radiation Oncology Department Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Panel Member, Radiation Oncology Residency Interview Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, Radiation Oncology HDR Brachytherapy Pilot Program Group, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Genitourinary Lead, Radiation Oncology Residency Clinical Competency Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, Radiation Oncology Remote Simulation Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, FLASH Working Group, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, MD Anderson Bladder Working Group, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Editorial Activities

      Editor, Brachytherapy, 2025 - Present

      Genitourinary Section Editor, Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE), 2024 - Present

      Honors & Awards

      2026 - PresentThe Luis Delclos Excellence in Teaching Award, The University of MD Anderson Cancer Center
      2025 - PresentJohn Quale Travel Fellowship Award, Bladder Cancer Advocacy Network (BCAN)
      2025 - PresentSelected as Associate Medical Director of The Proton Center, The University of Texas MD Anderson Cancer Center
      2025 - PresentSelected as New Practitioner Commitee Chair, American College of Radiation Oncology
      2025 - PresentTop Performer - Top 10% CAHPS Patient Experience Survey
      2025 - 2027Elected as American College of Radiology (ACR) Texas Radiological Society Alternate Councilor
      2024Elected as Member at Large, Texas Radiological Society
      2024American College of Radiation Oncology Mentorship Award, American College of Radiation Oncology (ACRO)
      2024Selected as Bone Metastasis Clinic Director, MD Anderson Cancer Center
      2024ASTRO Annual Meeting Abstract Award, American Society for Radiation Oncology
      2024Top Performer - Top 1% CAHPS Survey Performance, MD Anderson Physician Referral Service
      2023Machtay Young Investigator Travel Award, NRG Oncology
      2023National Top Provider, National Patient Experience Survey, CAHPS, MD Anderson Cancer Center

      Professional Memberships

      American College of Radiation Oncology

      2025 - Present

      American College of Radiation Oncology (ACRO)

      2025 - Present

      European Association of Urology

      2024 - Present

      Texas Radiological Association

      2024 - Present

      Bladder Cancer Advocacy Network (BCAN)

      2023 - Present

      Texas Radiological Society (TRS)

      2022 - Present

      American Society of Clinical Oncology (ASCO)

      2022 - Present

      ECOG-ACRIN Radiation Committee

      2022 - Present

      NRG Oncology

      2021 - Present

      American College of Radiation Oncology (ACRO)

      2019 - Present

      American College of Radiology (ACR)

      2018 - Present

      Radiation Research Society (RADRES)

      2018 - Present

      American Radium Society (ARS)

      2018 - Present

      Radiologic Society of North America (RSNA)

      2017 - Present

      Missouri Radiological Society

      2017 - 2022

      American Society of Therapeutic Radiation Oncology (ASTRO)

      2016 - Present

      American College of Physicians (ACP)

      2013 - 2017

      Selected Presentations & Talks

      Local Presentations

      1. 2026. MRI Guided, Adaptive Stereotactic Radiation for Prostate Cancer. Invited. IGCT Seminar Series 2026. Houston, Texas, US.
      2. 2023. ASTRO GU Highlights 2023. Houston, Texas, US.
      3. 2023. Bladder Cancer Management Series. Houston, Texas, US.

      Regional Presentations

      1. 2026. Locally Advanced Bladder Cancer Roundtable. Invited. Houston, Texas, US.
      2. 2025. Bone Metastasis: Oncologic Management. Invited. Invited Speaker: Radiation Oncology and Orthopedic Oncology Society, US.
      3. 2025. Panel Discussion: Multidisciplinary Management of Muscle-Invasive Bladder Cancer. Panelist. Astellas HOLI: Educational Seminar on Muscle-Invasive Bladder Cancer (MIBC), US.

      National Presentations

      1. 2026. Locally Advanced Bladder Cancer, Radiation Therapy: A Challenging Mission. Invited. UT MD Chris Woods Urologic Oncology Conference. San Antonio, Texas, US.
      2. 2026. Radiation Oncology Medical Student Q&A. OnlineOnly. Virtual Oncology Series for Medical Student. Arlington, Virginia, US.
      3. 2025. Trimodality Therapy: Bladder Preserving Strategies and Liquid Biopsies. Invited. Bladder Cancer Advocacy Network (BCAN) Think Tank, US.
      4. 2025. GU: Bladder Cancer Advances and Radiotherapy. Texas Radiological Society: Virtual Grand Rounds, US.
      5. 2025. Bladder Cancer Preservation and Evolution of Radiation Therapy. Invited. Mel Klein Lectureship 2025, US.
      6. 2025. Bladder Cancer Radiotherapy: 2025 Updates and Future Advances. Invited. Virtual Lecture Series: WashU Genitourinary Resident Seminar, US.
      7. 2025. EV/IO and the Evolution of Radiation for Bladder Cancer. Invited. Bladder Cancer Advocacy Network (BCAN) Think Tank, US.
      8. 2025. The Evolution of Radiation for Bladder Cancer. Invited. Christopher G Wood Advances in Urologic Oncology Symposium. Austin, TX, US.
      9. 2025. Milestones in Metastatic Prostate Cancer (GU 5 Scientific Session). Invited. ASTRO 2025. San Francisco, CA, US.
      10. 2024. Seminoma Management: Panelist. Conference. Christopher G Wood Advances in Urologic Oncology Symposium 2024. Austin, TX, US.
      11. 2024. Muscle Invasive Bladder Cancer: Radiation Oncology Challenging Cases. Conference. Mel Klein Lectureship in Bladder Cancer, US.
      12. 2024. MD Anderson Hypofractionated Intensity Modulated Radiation for Prostate Cancer Trial: 15 Year Update. Conference. ASTRO 2024. Washington, DC, US.
      13. 2024. Trimodality Therapy for Bladder Cancer and Organ Preservation. Invited. Invited Speaker-The University of Texas San Antonio Radiation Oncology Residency Virtual Visiting Lecturship Series, US.
      14. 2024. Personalizing Prostate Cancer Care with a Prognostic Biomarker. Invited. American College of Radiation Oncology Podcast Series, US.
      15. 2024. Trimodality Therapy and Bladder Preservation: Bladder Cancer. Invited. Radiation Oncology Virtual Lecture Series, US.
      16. 2024. Trimodality Therapy for Bladder Cancer and Organ Preservation. Invited. Invited Speaker- RUSH MD Anderson Cancer Center Radiation Oncology Residency Virtual Seminar Series. Chicago, Illinois, US.
      17. 2024. Muscle Invasive Bladder Cancer and Node Positive Bladder Cancer: Trimodality Therapy. Invited. Network Radiation Oncology (NERO) 2024, US.
      18. 2023. Meet the Experts: MD Anderson Cancer Center, ASTRO Annual Meeting 2023. Invited, US.
      19. 2023. Trimodal Bladder Preserving Therapy. Invited. Mel Klein Lectureship Bladder Cancer 2023. Houston, Texas, US.
      20. 2023. Bladder Preserving Strategies: Radiation Oncology Perspective. Conference. Bladder Preserving Strategies: Radiation Oncology Perspective. Austin, TX, US.
      21. 2023. Trimodality Therapy for Bladder Cancer. Invited. International Bladder Cancer Group Annual Meeting, US.
      22. 2023. Updates on Bladder Cancer Trimodal Therapy and Bladder Preservation. Conference. Mel Klein Lectureship in Bladder Cancer, US.
      23. 2020. Navigating the Radiation Oncology 2021 Match. Conference. Navigating the Radiation Oncology 2021 Match, US.
      24. 2020. Amiodarone Use and Radiation Pneumonitis in Patients Undergoing Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer. Conference. Amiodarone Use and Radiation Pneumonitis in Patients Undergoing Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer, US.
      25. 2020. Head and Neck Quad Shot Using CT Based Adaptive Treatment on a Ring Gantry LINAC. Conference. Head and Neck Quad Shot Using CT Based Adaptive Treatment on a Ring Gantry LINAC, US.
      26. 2020. Stereotactic MR-Guided Adaptive Radiation Therapy for Inoperable Pancreatic Cancer Using a 5- Fraction Approach. Conference. Stereotactic MR-Guided Adaptive Radiation Therapy for Inoperable Pancreatic Cancer Using a 5- Fraction Approach, US.
      27. 2020. Early MRI Changes of Glioblastoma During Chemoradiotherapy and Implications for Treatment Planning. Conference. Early MRI Changes of Glioblastoma During Chemoradiotherapy and Implications for Treatment Planning, US.
      28. 2019. Multi-institutional Study of Pneumonitis after Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer. Conference. Multi-institutional Study of Pneumonitis after Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer. Chicago, IL, US.
      29. 2019. Prognostic significance of p16 in patients with cervical cancer receiving chemoradiation. Conference. Prognostic significance of p16 in patients with cervical cancer receiving chemoradiation. Dana Point, CA, US.
      30. 2017. A Single Institution Experience with the Utility of Brain Simultaneous 18F-FDG-PET/MRI to Differentiate Tumor Recurrence from Radiation Necrosis. Conference. A Single Institution Experience with the Utility of Brain Simultaneous 18F-FDG-PET/MRI to Differentiate Tumor Recurrence from Radiation Necrosis. Colorado Springs, CO, US.
      31. 2017. Multiparametric Advanced MR and FDG PET Imaging is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma. Conference. Multiparametric Advanced MR and FDG PET Imaging is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma. San Diego, CA, US.
      32. 2017. A Competing Risk Nomogram to Predict Severe Late Toxicity After Modern Re-Irradiation for Squamous Carcinoma of the Head and Neck. Conference. A Competing Risk Nomogram to Predict Severe Late Toxicity After Modern Re-Irradiation for Squamous Carcinoma of the Head and Neck. San Diego, CA, US.
      33. 2017. Correlation & Prognostic Significance of Pre-Treatment F-FDG- and Cu-ATSM-PET/CT for Cervical Cancer. Conference. Correlation & Prognostic Significance of Pre-Treatment F-FDG- and Cu-ATSM-PET/CT for Cervical Cancer. San Diego, CA, US.
      34. 2016. Association of Post- Treatment Positron Emission Tomography Response with Local-regional Control and Survival after Radiation for Vulvar Cancer. Conference. Association of Post- Treatment Positron Emission Tomography Response with Local-regional Control and Survival after Radiation for Vulvar Cancer. Chicago, IL, US.
      35. 2016. Refining Patient Selection for Re-Irradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-Institution Cohort Study by the MIRI Collaborative. Conference. Refining Patient Selection for Re-Irradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-Institution Cohort Study by the MIRI Collaborative. Boston, MA, US.
      36. 2015. Acid-Sensing Ion Channels Control Locomotor and Rewarding Effects of Amphetamine. Conference. Acid-Sensing Ion Channels Control Locomotor and Rewarding Effects of Amphetamine. Chicago, IL, US.
      37. 2015. Regulation of Locomotor Activity following Amphetamine Administration by Acid-sensing Ion Channel in Adult Mice. Conference. Regulation of Locomotor Activity following Amphetamine Administration by Acid-sensing Ion Channel in Adult Mice. Washington, DC, US.
      38. 2011. Adenosinergic Modulation of Spatial Memory and Motor Function in Parkinson’s disease. Conference. Adenosinergic Modulation of Spatial Memory and Motor Function in Parkinson’s disease. Saint Louis, MO, US.

      International Presentations

      1. 2026. CONSOLIDATE: Phase I/II study of radiotherapy combined with enfortumab vedotin (EV) for locally advanced bladder cancer with paired ctDNA and utDNA. OnlineOnly. ASCO GU 2026. Houston, US.
      2. 2025. Dose-escalated radiation vs conventionally fractionated radiation for prostate cancer. OnlineOnly. VJOncology Journal Club, US.
      3. 2025. The Role of Metastasis-Directed Radiotherapy in Oligometastatic Urothelial Carcinoma. OnlineOnly. ASCO GU, US.
      4. 2025. UroToday: EAU 2025 Rapid Fire Debates (Management of positive soft tissue margins after radical cystectomy. What about isolated pelvic recurrences after cystectomy?). OnlineOnly. EAU, US.
      5. 2025. Bladder Cancer: Common problems and controversies. Invited. European Assocation of Urology 2025. Madrid, ES.
      6. 2025. Assessing Baseline Bladder Function for Patients Considering Trimodal Therapy. OnlineOnly. UroToday, US.
      7. 2025. Optimizing Prostate Cancer Management: Leveragin PSMA Imaging to Enhance Treatment Strategies. OnlineOnly. Cancer Network, US.

      Formal Peers

      1. 2020. Navigating the Radiation Oncology Match. Invited, US.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - Present
      Title:IFSCT Award for Protocol 2024-0001 NRG GU010
      Funding Source:The University of Texas MD Anderson Cancer Center
      Role:PI
      Date: 2026 - Present
      Title:IFSCT Award for Protocol 2025-1485 (NRG GU015)
      Funding Source:The University of Texas MD Anderson Cancer Center
      Role:PI
      Date: 2026 - Present
      Title:Cancer Network Research Support Grant
      Funding Source:MD Anderson Cancer Network
      Role:PI
      Date: 2024 - Present
      Title:Myriad Industry Grant
      Funding Source:Myriad Genetics
      Role:PI
      Date: 2021 - 2022
      Title:American College of Radiation Oncology (ACRO) Resident Seed Grant
      Funding Source:American College of Radiation Oncology (ACRO)
      Role:Co-PI
      Date: 2019 - 2022
      Title:Varian Medical Systems Research Grant
      Funding Source:Varian Medical Systems
      Role:Co-PI
      Date: 2015 - 2017
      Title:Alpha Omega Alpha (AOA) Carolyn L. Kuckein Student Research Fellowship Grant
      Funding Source:Alpha Omega Alpha (AOA)
      Role:PI

      Selected Publications

      Peer-Reviewed Articles

      1. El Kouzi, Z, Mohammed, MA, Rooney, M, Kouzy, R, Chen, JJ, Shah, SJ, Al Bitar, T, Gadoue, S, Hassanzadeh, CJ, Frank, SJ, Tran, P, Tang, C, Choi, S, Park, RJ, Hoffman, K, McGuire, SE, Mok, H, Nguyen, Q, Samman, AB, Rahman, Z, Shelan, M, Eid, T, Mohamad, O. Association between author specialty and reported outcomes in non-randomized comparisons of prostatectomy versus radiation. JNCI Cancer Spectrum 10(4), 2026. e-Pub 2026. PMID: 42390011.
      2. Gupta H, Qureshi MM, Kouzi ZE, Rooney MK, Hassanzadeh C, Shelan M, Tran PT, Mok H, Frank S, Bitar TA, Shah S, Park RJ, Tang C, Choi S, Hoffman K, Mayo L, McGuire S, Nguyen Q, Truong MT, Gadoue SM, Mohamad O. Modern Trends in the Use of Postoperative Radiotherapy After Prostatectomy in Prostate Cancer. Prostate Cancer Prostatic Dis. e-Pub 2026.
      3. McDonald J, La Cruz DD, Pinnix CC, Bronk JK, Hassanzadeh C, Holliday EB, Lee A, Mitchell MP, Mitra D, Perni S, Taku N, Gunther JR. Managing Radiation Therapy Treatment Delivery Challenges: Impact of an Interprofessional Educational Series for Radiation Therapists and Radiation Oncology Residents. Journal of Cancer Education, 2026. e-Pub 2026.
      4. Sutera P, Shetty A, Song Y, Mendes A, Yamashita R, Chang L, Wang J, Esteva A, Huang H, Todorovic T, Ramator M, Guler O, Dirix P, Mercier C, Pasquier D, Magné N, Créhange G, Park R, Rooney M, Shah S, Choi S, Frank S, Hassanzadeh C, Hoffman K, McGuire S, Nguyen Q, Feng M, Patel K, Tang C, Simone N, Marchionni L, Ren L, Sawant A, Nguyen P, Kiess A, Song D, DeWeese T, Supiot S, Ost P, Onal C, Berlin A, Fertig E, Kagohara L, Lotan T, Zhao S, Deek M, Tran AP. Interpreting the Model: Biologic Pathways Underlying a Clinically Validated Multimodal Digital Pathology AI Biomarker in Metastatic Prostate Cancer. Cancer Discovery. e-Pub 2026.
      5. Shin K, Buszek SM, Antonoff MB, Ward JF, Tang C, Hassanzadeh C, Rooney M, Nguyen Q, McGuire SE, Hoffman K, Frank SJ, Tran PT. Salvage Radiotherapy After Cryotherapy or High-Intensity Focused Ultrasound for Recurrent Prostate Cancer: A Modern Cohort Analysis. Urology. e-Pub 2026.
      6. McCullum, L, van Rijssel, MJ, Hwang, KP, Ding, Y, Tang, C, Hassanzadeh, CJ, Yang, J, Balter, PA, Wang, J, Fuller, C, Subashi, ED. Feasibility of longitudinal relaxation rate mapping with non-Cartesian sampling and compressed sensing on a 1.5 T magnetic resonance linear accelerator. Physics and Imaging in Radiation Oncology 39, 2026. e-Pub 2026. PMID: 42212205.
      7. Hassanzadeh C. Skin Toxicity and Survival With Enfortumab Vedotin–Pembrolizumab in Advanced Urothelial Carcinoma. JAMA Network Open, 2026. e-Pub 2026.
      8. Hamkins HM, Tam KH, Sobremonte A, Jogi S, Koay E, Hassanzadeh C, Segars P, Tyagi N, Subashi E. Automated Design of Patient-Specific 4D-Printed Phantoms for Quality Assurance of Adaptive Radiotherapy on a 1.5T MR-Linac. 3D Printing in Medicine, 2026.
      9. Nalin AP, Hoffman K, Campbell MT, Lin JK, Shah AY, Johns A, Prajapati S, Lozano C, Ward JF, Dai J, Park R, Tang C, Mok H, Rooney M, Mohamad O, Choi S, Tran PT, Hassanzadeh CJ. Clinical outcomes of proton versus conventional radiation for Stage IIA and IIB seminoma. Clinical Genitourinary Cancer, 2026.
      10. Shin K, Rooney M, Swanson D, Tang C, Nguyen Q, Mok H, Hassanzadeh C, Hoffman K, Frank S, Tran P, Choi S. Impact of Short-Term Androgen Deprivation Therapy on Survival Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated with Definitive Proton Beam Radiotherapy. Radiotherapy and Oncology, 2026.
      11. Shin K, El Kouzi Z, Swanson D, Mohamad O, Rooney M, Tang C, Mok H, Hassanzadeh C, Nguyen QN, McGuire SE, Hoffman KE, Frank SJ, Tran PT, Zurita AJ, Chapin BF, Surasi DS, Corn P, Choi S. Outcomes of N1 and M1a Prostate Cancer Treated with Prostate and Whole-Pelvic Radiotherapy in the Contemporary Systemic Therapy Era. International Journal of Radiation Oncology - Biology - Physics, 2026.
      12. Rooney MK, Cozma A, Kouzi ZE, Kouzy R, Hassanzadeh C, Hsu I, Phillips T, Holly Clark B, Cunha A, Shelan M, Klopp A, Phuoc T Tran, Mok H, Frank S, Vijayan S, Kudchadker R, Yu H, Kim Y, Prajapati S, Mohamad O. Introduction of a High-dose Rate Prostate Brachytherapy Program at a Tertiary Care Center: A Practical Guide for Program Development and Implementation. JNCI Cancer Spectrum, 2026.
      13. Kouzy, R, Ibrahim, I, Nemr, P, Vinjamuri, S, Ballout, B, Diaz, JG, Figueroa, DN, Alam, MB, Kouzi, ZE, Hassanzadeh, CJ, Mohamad, O, Weil, CR, Colbert, LE, Klopp, AH. Evaluation of AI chatbot responses to brachytherapy frequently asked questions. Brachytherapy 25(2):275-282, 2026. e-Pub 2026. PMID: 41407567.
      14. Marqueen, KE, Corrigan, KL, Prajapati, S, Kudchadker, RJ, Manzar, G, Cha, E, Mok, H, Tang, C, Hassanzadeh, CJ, Mohamad, O, Frank, SJ. Assessment of brachytherapy-induced prostate edema on postimplant dosimetric analysis in patients treated with magnetic resonance imaging–assisted radiosurgery (MARS). Brachytherapy 25(1):24-30, 2026. e-Pub 2026. PMID: 41271489.
      15. Pearce J, Pandey P, Hassanzadeh C, Smith BD, Chen A, Kemp A, Bird J, Patel S, Satcher R, Lin P, Colbert L, Mitchell M, Grosshans D. Preoperative Radiotherapy for Appendicular Bone Metastases: Outcomes. BMJ Supportive & Palliative Care, 2026. e-Pub 2026.
      16. Su S, Gao S, Liang X, Casey K, Mehrens H, Yu ZH, Kim Y, Hassanzadeh C, Tang C, Tran PT, Schofield D, Balter P, Han EY. Simulated Online Adaptive Radiotherapy on C-arm Linacs: Integrating High Resolution Cone-Beam CT into Abdominal Stereotactic Body Radiation Therapy. Journal of Applied Clinical Medical Physics, 2026. e-Pub 2026.
      17. Carriere P, Alhalabi O, Gao J, Shah A, Goswami S, Campbell M, Lin R, Mayo L, Mohamad O, Hoffman K, Mok H, Lozano C, Kamat A, Navai N, Bree K, Lee B, Guo C, Rooney M, Tang C, Choi S, Hassanzadeh C. Metastasis-Directed Radiotherapy for Oligometastatic Urothelial Carcinoma of the Bladder and Upper Tract. Bladder Cancer, 2026. e-Pub 2026.
      18. Netherton TJ, Aggarwal A, Alakayleh Q, Beadle BM, Brooks C, Burger H, Cardenas CE, Celaya A, Chacko S, Chung C, Douglas R, Basha DE, Frank S, Fuentes D, Hassanzadeh C, Helbrow J, Hoskin P, Khan M, Kroiss M, Leone A, Lin L, Mumme R, Nguyen C, Nguyen Q, Olanrewaju A, Parameshwaran J, Pollard-Larkin J, Poenisch F, Shah S, Sosa AJ, Tang C, Yu Z, Zhang L, Court LE. AI-Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning with the Radiation Planning Assistant. JCO Global Oncology, 2026. e-Pub 2026.
      19. Rooney M, Patel KR, Shah S, Gregg JR, Frank S, Hoffman K, Park R, Hassanzadeh CJ, Choi S, McGuire S, Nguyen Q, Troncoso P, Subudhi SK, Zhao SG, Pettaway CA, Corn P, Tang C, Tran PT. Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer. Cancer, 2026. e-Pub 2026.
      20. Patel SR, Myers AA, Black JB, Talwar³ R, Williams S, Mouw⁵ KW, Necchi⁶ A, Hensley⁷ PJ, Lerner⁸ SP, Li⁹ R, Meeks¹⁰ JJ, Bree¹ K, Galsky¹¹ MD, Campbell¹² M, Hassanzadeh C, Alhalabi¹² O, Psutka¹⁴ SP, Plimack¹⁵ ER, Sadeghi¹⁶ S, Gupta¹⁷ S, Powles¹⁸ T, Navai¹ N, Joyce³ DD, Kamat AM. Budget Impact of Modern Bladder-Preservation Strategies for Muscle-Invasive Bladder Cancer. e-Pub 2026.
      21. Mohamad O, Kouzi ZE, Kouzy R, Choi S, Mok H, Hoffman K, Nguyen Q, Hassanzadeh CJ, Tang C, Park RJ, Shah SJ, McGuire SE, Mayo LL, Kim Y, Prajapati S, Vijayan S, Kudchadker RJ, Bruno TL, Frank SJ. Safety and Early Outcomes of Proton Therapy and Low-Dose Rate Brachytherapy Boost for Patients with Prostate Cancer. Brachytherapy, 2025. e-Pub 2025. PMID: 40024668.
      22. Kishan AU, Sun Y, Tree AC, Hall E, Dearnaley D, Catton CN, Lukka HR, Pond G, Lee W, Sandler HM, Feng FY, Nguyen PL, Incrocci L, Heemsbergen W, Pos FJ, Horwitz E, Wong JK, Hoffman KE, Hassanzadeh C, Kuban DA, Arcangeli S, Sanguineti G, Supiot S, Crehange G, Latorzeff I, Kalbasi TR, Steinberg ML, Valle LF, Loblaw A, Nikitas J, Roy S, Zaorsky NG, Jia AY, Spratt DE. Hypofractionated Radiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in MARCAP Consortium. Lancet Oncology, 2025. e-Pub 2025. PMID: 40112848.
      23. Hassanzadeh, CJ, Mohamad, O, Bruno, TL, Wang, L, Kudchakar, R, Bathala, TK, Sanders, JW, Mok, H, McGuire, SE, Kuban, DA, Hoffman, K, Nguyen, Q, Park, RJ, Thames, HD, Corn, P, Chapin, BF, Choi, S, Tang, C, Frank, SJ. Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences. Brachytherapy 24(2):231-237, 2025. e-Pub 2025. PMID: 39755443.
      24. Attar-Olyaee R, Kouzy R, Rooney MK, Hassanzadeh CJ, Hoffman K, Li JJ, Mohamad O. Cancer Risk Concerns and Communication Gaps Regarding GLP-1 Medications. JAMA Network Open 8(7):e2521878, 2025. e-Pub 2025. PMID: 40679829.
      25. Hassanzadeh, CJ, Kuban, DA, Pasyar, S, Bassett Jr, R, Troncoso, P, Ansari, M, Schlembach, PJ, McGuire, SE, Nguyen, Q, Frank, SJ, Mok, H, Mohamad, O, Park, RJ, Tang, C, Du, W, Kudchadker, RJ, Choi, S, Hoffman, K. Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer. Journal of Clinical Oncology 43(18):2044-2048, 2025. e-Pub 2025. PMID: 40367400.
      26. Liu W, Schiff JP, Hassanzadeh C, Miller K, Hatscher C, Beckert R, Price A, Daly M, Brenneman R, Henke L, Apicelli A, Moravan M, Thorstad W, Laugeman E. Palliative expeditiously adaptive quad shot radiotherapy for head and neck cancers (PEAQ-RT). Clin Transl Radiat Oncol 54, 2025. e-Pub 2025. PMID: 40703666.
      27. Netherton TJ, Aggarwal A, Alakayleh Q, Beadle BM, Brooks C, Burger H, Cardenas CE, Celaya A, Chacko S, Chung C, Douglas R, Basha DE, Frank S, Fuentes D, Hassanzadeh C, Helbrow J, Hoskin P, Khan M, Kroiss M, Leone A, Lin L, Mumme R, Nguyen C, Nguyen Q, Olanrewaju A, Parameshwaran J, Pollard-Larkin J, Poenisch F, Shah S, Sosa AJ, Tang C, Yu Z, Zhang L, Court LE. AI-Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning with the Radiation Planning Assistant (RPA). medRxiv, 2025. e-Pub 2025.
      28. McCullum L, van Rijssel MJ, Hwang K, Ding Y, Tang C, Hassanzadeh C, Yang J, Balter PA, Wang J, Fuller CD, Subashi ED. Feasibility of Longitudinal Relaxation Rate Mapping with Non-Cartesian Sampling and Compressed Sensing on a 1.5T MR-Linac. med Rxiv, 2025. e-Pub 2025.
      29. Zhao, Y, Cozma, A, Ding, Y, Perles, LA, Reiazi, R, Chen, X, Kang, AM, Prajapati, S, Yu, H, Subashi, ED, Brock, K, Wang, J, Beddar, S, Lee, B, Mohammedsaid, M, Cooper, S, Westley, RL, Tree, A, Mohamad, O, Hassanzadeh, CJ, Mok, H, Choi, S, Tang, C, Yang, J. Upper Urinary Tract Stereotactic Body Radiotherapy Using a 1.5 Tesla Magnetic Resonance Imaging-Guided Linear Accelerator. Cancers 16(23), 2024. e-Pub 2024. PMID: 39682173.
      30. Carriere P, Alhalabi O, Gao J, Mohamad O, Campbell MT, Shah A, Goswami S, Bree K, Lee B, Navai N, Mok H, Mayo L, Guo C, Nguyen Q, McGuire S, Park R, Shah S, Hoffman K, Frank S, Tang C, Choi S, Kamat A, Hassanzadeh C. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clinical and Translational Radiation Oncology, 2024. e-Pub 2024. PMID: 39403573.
      31. Thomas H, Chen JJ, Shaheen H, Sabbagh A, Abdul-Baki H, Chau OW, Malik N, Ayoub L, Hassanzadeh C, Hsu I, Mohamad O. Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series. Journal of Contemporary Brachytherapy, 2024. e-Pub 2024. PMID: 38584887.
      32. Razavian NB, Schutz AN, Chang L, Benitez CM, Sandoval ML, Sharifzadeh Y, Sherer MV, Merfeld EC, Washington C, McKenzie GW, Khan Q, Hassanzadeh CJ, Arbab M. Evaluating the Utility of Webinars on the Radiation Oncology Residency Application Process in the COVID-19 Era. Applied Radiation Oncology, 2023. e-Pub 2023.
      33. Xu, L, Pacia, CP, Gong, Y, Hu, Z, Chien, CY, Yang, L, Gach, HM, Hao, Y, Hassanzadeh, CJ, Huang, J, Leuthardt, EC, Chen, H. Characterization of the Targeting Accuracy of a Neuronavigation-Guided Transcranial FUS System In Vitro, In Vivo, and In Silico. IEEE Transactions on Biomedical Engineering 70(5):1528-1538, 2023. e-Pub 2023. PMID: 36374883.
      34. Hassanzadeh C, Mirza K, Kalaghci B, Fallahian F, Chin RI, Roy A, Stowe H, Low G, Pedersen K, Wise P, Glasgow S, Roach M, Henke L, Badiyan S, Mutch M, Kim H. Lateral Pelvic Nodal Management and Patterns of Failure in Patients Receiving Short Course Radiation for Locally Advanced Rectal Cancer. Dis Colon Rectum 67(1):54-61, 2023. e-Pub 2023. PMID: 37787502.
      35. Thomas H, Chen JJ, Abdul-Baki H, Sabbagh A, Shaheen H, Chau OW, Malik N, Ayoub A, Hassanzadeh C, Hsu I, Mohamad O. Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series. Brachytherapy 23(2):173-178, 2023. e-Pub 2023. PMID: 38160102.
      36. Arbab M, Chaurasia A, Merfeld E, Hassanzadeh C, Sherer M, Razavian N, Schutz A, Sandoval M, Holmes J, Puckett L, Dragun J, Schuster J. Formalized Mentorship in Radiation Oncology in the COVID Era: American College of Radiation Oncology Experience. Applied Radiation Oncology 10(12):18-24, 2021. e-Pub 2021.
      37. Magudia K, Ng TSC, Campbell SR, Balthazar P, Dibble EH, Hassanzadeh CJ, Lall N, Merfeld EC, Esfahani SA, Jimenez RB, Fields EC, Lightfoote JB, Ackerman SJ, Jeans EB, Englander MJ, DeBenedectis CM, Porter KK, Spalluto LB, Deitte LA, Jagsi R, Arleo EK. Family and Medical Leave for Diagnostic Radiology, Interventional Radiology, and Radiation Oncology Residents in the United States: A Policy Opportunity. Radiology 300(1):31-35, 2021. e-Pub 2021. PMID: 33847521.
      38. Hassanzadeh C, Rudra S, Ma S, Brenneman R, Huang Y, Henke L, Abraham C, Campian J, Tsien C, Huang J. Evaluation of interim MRI changes during limited-field radiation therapy for glioblastoma and implications for treatment planning. Radiother Oncol 158:237-243, 2021. e-Pub 2021. PMID: 33587967.
      39. Hassanzadeh C, Rudra S, Bommireddy A, Hawkins WG, Wang-Gillam A, Fields RC, Cai B, Park J, Green O, Roach M, Henke L, Kim H. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Adv Radiat Oncol 6(1):100506, 2021. e-Pub 2021. PMID: 33665480.
      40. Hassanzadeh C, Roach M, Rich K, Karraker P, Robinson C, Michalski J, Perkins S, Huang J, Tsien C, Abraham C. Adherence of US Insurance Payer Policies to the American Society of Radiation Oncology Stereotactic Radiosurgery Model Policy. Pract Radiat Oncol 10(4):e250-e254, 2020. e-Pub 2020. PMID: 32004704.
      41. Hassanzadeh C, Sita T, Savoor R, Samson PP, Bradley J, Gentile M, Roach M, Mohindra N, Waqar S, Kruser TJ, Robinson C. Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer. J Thorac Dis 12(11):6690-6700, 2020. e-Pub 2020. PMID: 33282370.
      42. Ward MC, Lee NY, Caudell JJ, Zajichek A, Awan MJ, Koyfman SA, Dunlap NE, Zakem SJ, Hassanzadeh C, Marcrom S, Boggs DH, Isrow D, Vargo JA, Heron DE, Siddiqui F, Bonner JA, Beitler JJ, Yao M, Trotti AM, Riaz N, (MIRI) Collaborative MR. A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck. Oral Oncol 90:80-86, 2019. e-Pub 2019. PMID: 30846182.
      43. Lin AJ, Hassanzadeh C, Markovina S, Schwarz J, Grigsby P. Brachytherapy and survival in small cell cancer of the cervix and uterus. Brachytherapy 18(2):163-170, 2019. e-Pub 2019. PMID: 30563743.
      44. Brenneman RJ, Sharifai N, Fischer-Valuck B, Hassanzadeh C, Guzelian J, Chrisinger JSA, Michalski JM, Oppelt P, Baumann BC. Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma. Front Oncol 9(SEP):922, 2019. e-Pub 2019. PMID: 31616634.
      45. Caudell JJ, Ward MC, Riaz N, Zakem SJ, Awan MJ, Dunlap NE, Isrow D, Hassanzadeh C, Vargo JA, Heron DE, Marcrom S, Boggs DH, Reddy CA, Dault J, Bonner JA, Higgins KA, Beitler JJ, Koyfman SA, Machtay M, Yao M, Trotti AM, Siddiqui F, Lee NY, (MIRI) Collaborative MR. Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis. Int J Radiat Oncol Biol Phys 100(3):606-617, 2018. e-Pub 2018. PMID: 29413274.
      46. Ward MC, Riaz N, Caudell JJ, Dunlap NE, Isrow D, Zakem SJ, Dault J, Awan MJ, Vargo JA, Heron DE, Higgins KA, Beitler JJ, Marcrom S, Boggs DH, Hassanzadeh C, Reddy CA, Bonner JA, Yao M, Machtay M, Siddiqui F, Trotti AM, Lee NY, Koyfman SA, (MIRI) Collaborative MR. Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative. Int J Radiat Oncol Biol Phys 100(3):586-594, 2018. e-Pub 2018. PMID: 28865925.
      47. Vargo JA, Ward MC, Caudell JJ, Riaz N, Dunlap NE, Isrow D, Zakem SJ, Dault J, Awan MJ, Higgins KA, Hassanadeh C, Beitler JJ, Reddy CA, Marcrom S, Boggs DH, Bonner JA, Yao M, Machtay M, Siddiqui F, Y Lee AMT, Koyfman SA, Ferris RL, Heron DE. A Multi-Institution Comparison of SBRT and IMRT for Definitive Re-Irradiation of Recurrent or Second Primary Head and Neck Cancer. Int J Radiat Oncol Biol Phys 100(3), 2018. e-Pub 2018. PMID: 28899556.
      48. Rao YJ, Chundury A, Schwarz JK, Hassanzadeh C, DeWees T, Mullen D, Powell MA, Mutch DG, Grigsby PW. Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes. Adv Radiat Oncol 2(2):148-158, 2017. e-Pub 2017. PMID: 28740926.
      49. Rao YJ, Hassanzadeh C, Chundury A, Hui C, Siegel BA, Dehdashti F, DeWees T, Mullen D, Powell MA, Mutch DG, Schwarz JK, Grigsby PW. Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. Radiother Oncol 122(3):445-451, 2017. e-Pub 2017. PMID: 28063696.
      50. Rao YJ, Hassanzadeh C, Fischer-Valuck B, Chicoine MR, Kim AH, Perkins SM, Huang J. Patterns of care and treatment outcomes of patients with Craniopharyngioma in the national cancer database. J Neurooncol 132(1):109-117, 2017. e-Pub 2017. PMID: 28012064.
      51. Hassanzadeh C, Rao YJ, Chundury A, Rowe J, Ponisio MR, Sharma A, Miller-Thomas M, Tsien CI, Ippolito JE. Multiparametric MRI and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma. Front Oncol 7(AUG):178, 2017. e-Pub 2017. PMID: 28868256.
      52. Song N, Guan R, Jiang Q, Hassanzadeh CJ, Chu Y, Zhao X, Wang X, Yang D, Du Q, Chu XP, Shen L. Acid-sensing ion channels are expressed in the ventrolateral medulla and contribute to central chemoreception. Sci Rep 6:38777, 2016. e-Pub 2016. PMID: 27934921.
      53. Tran P, Sutera P, Shetty A, Song Y, Mendes A, Yamashita R, Stewart E, Wang J, Esteva A, Chen E, Huang H, Todorovic T, Ramotar M, Guler O, Dirix P, Mercier C, Pasquier D, Magne N, Crehange G, Park R, Rooney M, Shah S, Choi S, Frank S, Hassanzadeh C, Hoffman K, McGuire S, Nguyen Q, Showalter T, Patel K, Tang C, Simone N, Marchionni L, Ren L, Sawant A, Nguyen P, Kiess A, Song D, Deweese T, Supiot S, Ost P, Onal C, Berlin A, Fertig E, Kagohara L, Lotan T, Zhao S, Deek M. Interpreting the Model: Biologic Pathways Underlying a Clinically Validated Multimodal Digital Pathology AI Biomarker in Metastatic Prostate Cancer. Nature Cancer.

      Review Articles

      1. Carriere, P, Hassanzadeh, CJ. Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer. Journal of Clinical Medicine 15(13), 2026. e-Pub 2026. PMID: 42452561.
      2. Kwong F, Hassanzadeh C. Hypofractioned Particle Therapy: A Review of Clinical Data and Implications. The Cancer Journal: The Journal of Principles & Practice of Oncology, 2026. e-Pub 2026.
      3. Gupta S, Hensley PJ, Li R, Choudhury A, Daneshmand S, Faltas BM, Flaig TW, Grass G, Grivas P, Hansel DE, Hassanzadeh C, Kassouf W, Kukreja J, Mendoza-Valdés A, Moschini M, Mouw KW, Navai N, Necchi A, Rosenberg JE, Ross t JS, Siefker-Radtke AO, Taylor J, Willliams SB, Zlotta y AR, Buckley R, Kamat AM. Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. European Urology, 2025. e-Pub 2025. PMID: 40268594.

      Other Articles

      1. Kouzy R, Attar-Olyaee R, Rooney MK, Hassanzadeh CJ, Li JJ, Mohamad O QuaLLM-Health: An Adaptation of an LLM-Based Framework for Quantitative Data Extraction from Online Health Discussions. ArXiv Labs: Experimental Projecs with Community Collaborators, 2024.

      Editorials

      1. Kouzi ZE, Rooney M, Kouzy R, Hassanzadeh C, Tran PT, Mohamad O. Alternative Cancer Treatment Clinics in North America. JNCI.
      2. Court LE, Beadle B, Hassanzadeh, Skylar Gay CH, Netherton T, Howell R, Melancon A. Redesigning Residency Training with Artificial Intelligence: Implications for Efficiency, Quality, and Workforce Capacity, 2026.

      Abstracts

      1. Hassanzadeh C. Dosimetric Impact of Intrafraction Motion in MR-Guided SBRT to the Prostate and Dominant Lesion: Implications for the Use of Internal Target Volumes, Gating Strategies, and Delivery Efficiency. MRL Consortium 2026, 2026. e-Pub 2026.
      2. Hassanzadeh C, Barati R, Zhao Y, Kwong F, Hassanzadeh C, Ding Y, Rooney M, Mok H, Hoffman K, Park R, Choi S, Tran P, Tang C, Yang J. A foundation model-based human-in-the-loop approach for high-fidelity urethra segmentation in MR-guided prostate radiotherapy. MRL Consortium 2026, 2026. e-Pub 2026.
      3. Gupta H, Pandey P, Sanchez MA, Grosshans DR, Mitchell MP, Lin PP, Satcher RL, Patel SS, Bird JE, Matin SF, Prajapati S, Moon B, Colbert LE, Tang C, Desai M, Campbell MT, Rooney MK, Choi SL, Tran PT, Hassanzadeh CJ. Skeletal-Related Events Following Radiotherapy for Non-Spine Bone Metastases in Renal Cell Carcinoma. ASTRO 2026, 2026. e-Pub 2026.
      4. Gupta H, Qureshi MM, Kouzi ZE, Rooney MK, Hassanzadeh C, Shelan M, Tran PT, Mok H, Frank S, Bitar TA, Shah S, Park RJ, Tang C, Choi S, Hoffman K, Mayo L, McGuire S, Nguyen Q, Truong MT, Gadoue SM, Mohamad O. Modern Trends in the Use of Postoperative Radiotherapy After Prostatectomy in Prostate Cancer. Prostate Cancer and Prostatic Diseases, 2026. e-Pub 2026.
      5. Fetooh A, Pandey P, Kouzi ZE, Sanchez M, Colbert L, Mitchell M, Grosshans D, Heredia N, Hassanzadeh C. Multidisciplinary Rapid Access Bone Metastasis Clinic: Expeditious Workflow from Referral to Palliative Radiotherapy. ASTRO 2026, 2026. e-Pub 2026.
      6. Kouzi ZE, Chang E, Rooney M, Rauch G, Surabhi V, Surabhi A, Mohamad O, Tran P, Hassanzadeh C, Tang C, Mok H, Choi S, McGuire S, Hoffman K, Nguyen Q, Lee S, Frank S. Clinical Outcomes of Rectal Wall Infiltration Following Hydrogel Spacer Placement: A Single-Institution Retrospective Study. ASTRO 2026, 2026. e-Pub 2026.
      7. Carriere P, Alhalabi O, Kamat A, Gao J, Goswami S, Campbell M, Shah A, Jiang CY, Glover M, Bree K, Lee B, Navai N, Lozano C, Rooney MK, Mohamad O, Hoffman K, Choi S, Tran PT, Hassanzadeh C. CONSOLIDATE: Interim Results from a Phase I/II study of radiotherapy combined with enfortumab vedotin (EV) for locally advanced bladder cancer with paired translational ctDNA and utDNA. ASCO GU 2026, 2026. e-Pub 2026.
      8. Fetooh A, Pandey P, Kouzi ZE, Sanchez M, Colbert L, MD, Mitchell M, Grosshans D, Heredia N, Hassanzadeh C. Multidisciplinary Rapid Access Bone Metastasis Clinic: Expeditious Workflow from Referral to Palliative Radiotherapy. UT Health School of Public Health Symposium 2026, 2026. e-Pub 2026.
      9. Barati R, Kwong F, Hassanzadeh C, Choi S, Mohamad O, Mok H, Hoffman K, Park R, Tang C, Yang J, Zhao Y. Accelerating Clinical Translation: A Computationally Efficient Strategy for Institution-Specific Adaptation of Foundation Models for Prostate MRI Segmentation. AAPM 2026, 2026. e-Pub 2026.
      10. Lee T, Myers A, Patel S, Black J, Lee B, Bree K, Navai N, Hwang H, Guo C, Alhalabi O, Dinney C, Hassanzadeh C, Kamat AM. Young-onset bladder cancer (YOBC): clinicopathologic characteristics and oncologic outcomes in 260 patients from a single-center experience. EAU 2026, 2026. e-Pub 2026.
      11. Lee T, Patel S, Black J, Lee B, Bree K, Navai N, Hwang H, Dinney C, Hassanzadeh C, Kamat AM. Efficacy of intravesical Bacillus Calmette-Guerin after pelvic radiotherapy. EAU 2026, 2026. e-Pub 2026.
      12. Kouzi ZE, Mohammed MA, Rooney M, Kouzy R, Chen JJ, Rahman Z, Shah S, Hassanzadeh C, Frank S, Shelan M, Mohamad O. Association Between Author Specialty and Oncologic Outcomes in Non-randomized Comparisons of Radical Prostatectomy versus Radiation Therapy for Localized Prostate Cancer. ASTRO 2025, 2025. e-Pub 2025.
      13. Carriere P, Alhalabi O, Gao J, Shah A, Goswami S, Campbell M, Lin R, Mayo L, Mohamad O, Hoffman K, Mok H, Lozano C, Kamat A, Navai N, Bree K, Lee B, Guo C, Tang C, Choi S, Hassanzadeh C. Metastasis-directed radiotherapy in oligometastatic bladder and upper tract cancer: A single institution retrospective experience. ASCO GU Symposium 2025, 2025. e-Pub 2025.
      14. Patel P, Shah S, Mohamad O, Mok H, Choi S, Hoffman K, Tang C, Mayo L, Park R, McGuire S, Nguyen Q, Frank S, Chapin B, Graber W, Hassanzadeh C. Urinary Toxicity after External Beam Radiation Therapy for Prostate Cancer Following Transurethral Resection of Prostate or Laser Enucleantion. ASTRO 2025, 2025. e-Pub 2025.
      15. McCullum L, Yang J, Ding Y, Choi S, Hassanzadeh C, Koay E, Mohamad O, Tang C, Fuller C, Balter P, Wang J, Subashi E. Longitudinal Analysis of Log Files from Gated Delivery of Stereotactic Body Radiotherapy Using Motion Management in a 1.5 T MR-Linac. ASTRO 2025, 2025. e-Pub 2025.
      16. Nalin A, Hoffman K, Campbell M, Lin J, Shah A, Johns A, Prajapati S, Lozano C, Ward J, Park R, Tang C, Mok H, Mohamad O, Choi S, Hassanzadeh C. Outcomes of Stage IIA and Stage IIB Seminoma Treated with Definitive Radiation Therapy. ASTRO 2025, 2025. e-Pub 2025.
      17. Ansari M, Hoffman K, Mok H, Frank S, Nguyen Q, Tang C, McGuire S, Mayo L, Shah S, Prajapati S, Surasi DS, Pilie P, Lozano C, Mohamad O, Choi S, Hassanzadeh C. Clinical Outcomes of Salvage Nodal Radiotherapy for Prostate Cancer with Prior Radiotherapy. ASTRO 2025, 2025. e-Pub 2025.
      18. Mohamad O, Kouzi ZE, Choi S, Mok H, Hoffman K, Nguyen Q, Hassanzadeh CJ, Tang C, Shah SJ, McGuire SE, Mayo LL, Kim Y, Prajapati S, Vijayan S, Kudchadker RJ, Bruno TL, Kouzy R, Frank SJ. Safety and Early Outcomes of External Beam Radiation Therapy with Low-Dose Brachytherapy Boost in Patients with Prostate Cancer. ASTRO 2025, 2025. e-Pub 2025.
      19. Shin K, Choi S, Nguyen Q, Tang C, Hoffman KE, Hassanzadeh C, Mohamad O, Park RJ, Corn PG, Mcguire SE, Mok H, Ward JF, Buszek SM, Antonoff M. External beam radiation therapy for salvage after focal therapy as primary treatment in prostate adenocarcinoma. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
      20. Carriere P, Gao J, Alhalabi O, Qiao W, Lozano C, Campbell M, Shah A, Kovitz C, Goswami S, Desai M, Mok H, Tang C, Mohamad O, Mayo L, Bree K, Navai N, Lee B, Kamat A, Hoffman K, Choi S, Hassanzadeh C. CONSOLIDATE: Concurrent Radiotherapy with Enfortumab vedotin (EV) for Locally Advanced Bladder Cancer. ASTRO 2025, 2025. e-Pub 2025.
      21. Hassanzadeh, Alhalabi, Kamat, Gao, Lee, Tang, Mayo, Guo, Campbell, Shah, Nguyen, Shah, Mohamad, Park, Kuban, Goswami, Mok, Hoffman, Navai, Choi. Outcomes After Radiotherapy for Locally Advanced and Node Positive Muscle Invasive Bladder Cancer. European Society of Therapeutic Radiation Oncology 2024 Annual Conference, 2024. e-Pub 2024.
      22. Hassanzadeh C. Severe Genitourinary Events Following Definitive Radiation Therapy for Patients with Locally Advanced and Metastatic Bladder Cancer: A Single Institution Experience. ASTRO 2024, 2024. e-Pub 2024.
      23. Hassanzadeh C. Post Pelvic Radiotherapy Non Muscle Invasive Bladder Cancer Recurrence with BCG Salvage. American Urological Association 2024, 2024. e-Pub 2024.
      24. Chang E, Hassanzadeh C, Mohamad O, Choi S, Tang C, Nguyen Q. Stereotactic Body Radiotherapy for Prostate Cancer with Magnetic Resonance Imaging or Computed Tomography Guidance. American Society of Therapeutic Radiation Oncology 2024, 2024. e-Pub 2024.
      25. Zhao Y, Yang J, Perles L, Reiazi R, Chen X, Prajapati S, Subashi E, Yu H, Brock K, Wang J, Mohamad O, Hassanzadeh C, Choi S, Tang C, Ding Y. Respiratory Motion Management using Compression Belt for MR-guided Stereotactic Body Radiotherapy of Kidney Cancer. American Association of Physicists in Medicine 2024, 2024. e-Pub 2024.
      26. Mohamad O, Hassanzadeh C, Mok H, Tang C, Frank S. Proton Therapy with Brachytherapy Boost in Patients with Prostate Cancer: the MD Anderson Cancer Center Experience. American Brachytherapy Society 2024, 2024. e-Pub 2024.
      27. Liu W, Schiff JP, Hassanzadeh C, Miller K, Hatscher C, Beckert R, Daly M, Brenneman R, Apicelli A, Moravan M, Thorstad W, Laugeman E. Palliative Expeditiously Adaptive Quad Shot Radiotherapy for Head and Neck Cancers (PEAQ-RT). European Society of Therapeutic Radiation Oncology 2024, 2024. e-Pub 2024.
      28. Carriere, Alhalabi, Gao, Campbell, Kamat, Navai, Lee, Bree, Tang, Hoffman, Choi, Mohamad, Mok, Mayo, Hassanzadeh. Evaluating the efficacy of radiation therapy in MTAP-deficient bladder cancer. American Radium Society 2024 Annual Meeting, 2024. e-Pub 2024.
      29. Su, L, Pacia, C, Gong, Y, Chien, C-Y, Hu, Z, Yang, L, Gach, M, Hao, Y, Hassanzadeh, C, Huang, J, Leuthardt, E, Chen, H. Development of a neuronavigation-guided sonobiopsy device for glioblastoma patients. IEEE International Ultrasonics Symposium, 2022. e-Pub 2022.
      30. Arbab, M, Chaurasia, A, Hassanzadeh, C, Feng, C, Merfeld, E, Sherer, M, Fernandez, C, Everett, A, Schuster, J. Mentor/Mentee is How to Succeed – Summary of ACRO Mentorship Program 2020-21. American College of Radiation Oncology (ACRO) 2021 Annual Meeting, 2021. e-Pub 2021.
      31. Arbab, M, Chaurasia, A, Merfeld, E, Hassanzadeh, C, Feng, C, Sherer, M, Fernandez, C, Everett, A, Holmes, J, Puckett, L, Schuster, J. Formalized Mentorship in Radiation Oncology: Bridging Existing Gaps in Mentorship. ASTRO 2021 Annual Meeting, 2021. e-Pub 2021.
      32. Hassanzadeh, C, Fallahian, F, Low, G, Roy, A, Chin, R, Pedersen, K, Mutch, M, Glasgow, S, Henke, L, Badiyan, S, Kim, H. Lateral Pelvic Nodal Boost During Short Course Radiation Therapy for Locally Advanced Rectal Cancer. European Society of Radiation Oncology (ESTRO) 2021 Annual Meeting, 2021. e-Pub 2021.
      33. Hassanzadeh, C, Rudra, S, Ma, S, Abraham, C, Campian, J, Huang, J. Early MRI Changes of Glioblastoma During Chemoradiotherapy and Implications for Treatment Planning. ASTRO 2020 Annual Meeting, 2020. e-Pub 2020.
      34. Laugeman, E, Hassanzadeh, C, Pryser, E, Hugo, G, Mutic, S, Henke, L Thorstad L, W, Cai, B, Daly, M. Head and Neck Quad Shot Using CT Based Adaptive Treatment on a Ring Gantry LINAC. ASTRO 2020 Annual Meeting, 2020. e-Pub 2020.
      35. Hassanzadeh, C, Rudra, S, Bommireddy, A, Hawkins, W, Wang-Gillam, A, Fields, R, Cai, B, Park, J, Green, O, Roach, M, Henke, L, Kim, H. Stereotactic MR-Guided Adaptive Radiation Therapy for Inoperable Pancreatic Cancer Using a 5- Fraction Approach. European Society of Radiation Oncology (ESTRO) 2020 Annual Meeting, 2020. e-Pub 2020.
      36. Sita, T, Hassanzadeh, C, Savoor, R, Samson, P, Bradley, J, Gentile, M, Roach, M, Mohindra, N, Waqar, S, Robinson, C, Kruser, T. Multi-institutional Study of Pneumonitis after Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer. IASLC 2019 Annual Meeting, 2019. e-Pub 2019.
      37. Hassanzadeh, C, Srivastava, A, Markovina, S, Schwarz, J, Grigsby, P. Prognostic significance of p16 in patients with cervical cancer receiving chemoradiation. American Radium Society (ARS) 2019 Annual Meeting, 2019. e-Pub 2019.
      38. Ward, M, Caudell, J, Dunlap, N, Hassanzadeh, C, Reddy, C, Bonner, J, Koyfman, S, Riaz, N. A Competing Risk Nomogram to Predict Severe Late Toxicity After Modern Re-Irradiation for Squamous Carcinoma of the Head and Neck. ASTRO 2017 Annual Meeting, 2017. e-Pub 2017.
      39. Rao, Y (James) Y, Hassanzadeh, C, Chundury, A, Rowe, J, Ponisio, M, Sharma, A, Miller-Thomas, M, Tsien, C, Ippolito, J. Multiparametric Advanced MR and FDG PET Imaging is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma. ASTRO 2017 Annual Meeting, 2017. e-Pub 2017.
      40. Ippolito, J, Colen, R, Hassanzadeh, C, Rao, Y (James) Y, Ponisio, M, Tsien, C, Chinnaiyan, P, Rubin, J. Identification of a Clinically-Actionable Sexual Dimorphism in Glioblastoma Glycolysis. Society of Neuro-oncology 2017 Annual Meeting, 2017. e-Pub 2017.
      41. Hassanzadeh, C, Chundury, A, Rowe, J, Miller-Thomas, M, Tsien, C. A Single Institution Experience with the Utility of Brain Simultaneous 18F-FDG-PET/MRI to Differentiate Tumor Recurrence from Radiation Necrosis. Int J Radiat Oncol Biol Phys, 2017. e-Pub 2017.
      42. Hassanzadeh, C, Rao, Y, Schwarz, J, DeWees, T, Siegel, B, Dehdashti, F, Grigsby, P. Correlation & Prognostic Significance of Pre-Treatment F-FDG- and Cu-ATSM-PET/CT for Cervical Cancer. ASTRO 2017 Annual Meeting, 2017. e-Pub 2017.
      43. Hassanzadeh, C, Rao, Y (James) Y, Schwarz, J, Dewees, T, Mullen, D, Powell, M, Mutch, D, Grigsby, P. Association of Post- Treatment Positron Emission Tomography Response with Local-regional Control and Survival after Radiation for Vulvar Cancer. RSNA 2016 Annual Meeting, 2016. e-Pub 2016.
      44. Hassanzadeh, C, Jiang, Q, Sharma, A, Chu, X. Regulation of Locomotor Activity following Amphetamine Administration by Acid-sensing Ion Channel in Adult Mice. Journal of Academic Medicine, 2016. e-Pub 2016.
      45. Ward, M, Riaz, N, Caudell, J, Dunlap, N, Hassanzadeh, C, Reddy, C, Bonner, J, Koyfman, S. Refining Patient Selection for Re-Irradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-Institution Cohort Study by the MIRI Collaborative. ASTRO 2016 Annual Meeting, 2016. e-Pub 2016.
      46. Jiang, Q, Song, N, Guan, R, Hassanzadeh, C, Chu, Y, Wang, X, Shen, L, Chu, X. Acid-Sensing Ion Channels in Ventrolateral Medulla Contribute to Central Chemoreception. Society of Neuroscience 2016 Annual Meeting, 2016. e-Pub 2016.
      47. Presker, M, Albers, JA, Varade, N, Hassanzadeh, C, Anch, M. Adenosinergic Modulation of Spatial Memory and Motor Function in Parkinson’s disease. Saint Louis Research Symposium, 2011. e-Pub 2011.

      Web Publications

      1. Hassanzadeh C. ASTRO 2025: Discussant: Milestones in Metastatic Prostate Cancer, 2025.
      2. Carriere P, Alhalabi O, Gao J, Mohamad O, Campbell MT, Shah A, Goswami S, Bree K, Lee B, Navai N, Mok H, Mayo L, Guo C, Nguyen Q, McGuire S, Park R, Shah S, Hoffman K, Frank S, Tang C, Choi S, Kamat A, Hassanzadeh C. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer, 2024.
      3. Hassanzadeh C. ASTRO 2024: Hypofractionated, Dose-Escalated Radiation vs. Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase 3, Prospective, Randomized Controlled Trial, 2024.
      Read More
      Less

      Patient Reviews


      CV information above last modified September 10, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top